Key Takeaways
- Revenue down 4.6%, but domestic core grew 6%+: The headline decline masks a one-time shift of toothpaste sales to a subsidiary; excluding that, the India business was healthy, led by Cyclopam, Cital, and Sensoform.
- Margins compressed on mix, not just cost: Gross margin fell because the most profitable U.S. business was short ~₹20 cr, while lower-margin Europe grew. EBITDA margin hit 13%, with management committing to a minimum 15% exit by Q3.
- Regulatory overhang clearing, not cleared: Goa Plant 2 (sterile) remains under OAI, blocking new U.S. approvals, but the API site and testing lab got zero observations. Plant corrections are expected to finish in Q2, enabling consistent supply from Q3.
- Strategic pivot underway, with upfront costs: The company is shifting from U.S. out-licensing to its own front-end, investing in OTC toothpaste marketing, and retooling all plants for efficiency. Management frames this as a necessary turn that sacrifices near-term speed.
- What to watch next quarter: Whether Goa Plant 2 remediation stays on track for Q2 completion, the pace of U.S. revenue recovery in Q3, and any evidence that the efficiency capex is converting to margin expansion.
India Business: The Core Engine
- Headline decline is optical: Domestic formulation revenue fell from ₹213 cr to ₹200.2 cr, but this was entirely because Sensodent-K and KF sales moved to OTC subsidiary Warren Remedies. Excluding toothpaste, the domestic business grew at 6%+.
- Brand power concentrated: Cyclopam grew 30% internally and crossed ₹100 cr turnover last year. Cital grew 20%, Sensoform 30%, Karvol Plus 40%. The only weak brand was Febrex Plus at minus 8% internally.
- New launch FosHS: A single-dose fosfomycin treatment for uncomplicated UTIs, the first launch of its kind for the company, deals with all kinds of bacteria.
- OTC investment is a deliberate margin drag: The company is spending upfront on TV, physical media, and social media to build the Sensodent-K franchise in the OTC channel, which pressures near-term margins but aims to build a consumer brand.
Aditi Panandikar: "As I said earlier, as an organization, you are trying to make major strategic changes in keeping with market conditions, then sometimes you have to take turns, sometimes U-turn, sometimes right-angle turn. And while taking turns, it's not possible to keep the speed intact."
U.S. Business: Waiting on Goa Plant 2
- The bottleneck is regulatory, not demand: Goa Plant 2, the sterile unit, is under OAI status. The company continues to file new products with the FDA, but approvals will only come after the status is cleared. Current OAI does not stop shipping, and the company has been shipping.
- Goa Plant 1 is clean: Under VAI with no issues, but it houses only 3-4 solid oral products for the U.S.
- API site and testing lab got zero observations: The FDA successfully completed inspections at the API Kilo manufacturing plant and Indoco Analytical Solutions public testing lab, both with zero 483s.
- Supply recovery timeline: Most plant-related corrections are expected to complete in Q2, with consistent supply from Q3. U.S. line changes should also be complete by Q3.
- Pipeline is deep: 50-plus ANDAs are at various stages of approval. The company targets 30% U.S. growth on a CAGR basis over the next 2 years.
- Strategic shift from licensing to own front-end: The company is transitioning from out-licensing U.S. products (which generated milestones and royalties) to its own front-end, sacrificing near-term licensing fees for better recurring margins later.
Aditi Panandikar: "But most of the plants related corrections would get completed in the second quarter. So we expect from Q3 to be able to have consistent supply."
Margin Walk: Compression and Recovery Path
- Three drivers of EBITDA margin decline to 13%: (1) U.S. out-licensing fees and milestones are now near nil as the company keeps IP for itself; (2) upfront OTC toothpaste marketing investment in India; (3) efficiency-building measures at all sites, including increasing batch sizes and replacing old machines, which carry near-term costs.
- Gross margin compressed on product mix: The shortfall of ~₹20 cr in U.S. supply, which is the most profitable segment after India, plus a higher contribution from lower-margin Europe, pulled gross margin down.
- Cost containment working in absolute terms: Other expenses dropped sequentially from ~₹148 cr to ~₹120 cr, and are expected to stabilize at ₹110 cr to ₹120 cr per quarter going forward. Staff costs were also contained in absolute terms.
- Recovery commitment: Management expects margins to start normalizing from Q3, with a minimum of 15% EBITDA margin in Q3, if not more, and Q4 even stronger. The full-year minimum is 15%.
- No timeline for returning to 21%: When asked when earlier peak margins of 21% could be reached, management declined to give a timeline, saying "I don't think we can go from 13% to 21% immediately."
Europe: Building Beyond Paracetamol
- From contract manufacturing to own front-end: The company has migrated from pure contract manufacturing of commoditized products like paracetamol to owning its own marketing authorizations with a front-end presence. Many more products have been developed and filed, either approved or about to be approved.
- Paracetamol has bounced back: Better results are expected in Q2, Q3, and Q4, and the business will definitely do better than last year.
- Master manufacturing plan is the unlock: Once the master manufacturing plan is completed by end of Q2, Europe will be the division with maximum benefit. The company did not want too many geographies inside one plant, and the European business has a very healthy order book.
Capex and Capacity: The Payback Question
- Cumulative capex has not yet translated to sales: U.S. sterile investments were filed then hit by a regulatory setback, losing a couple of years. European business was parked as contract manufacturing while waiting for U.S. approvals, which were delayed by regulatory challenges.
- Management defends the strategy as correct but unlucky: Decisions were correct but hit by massive headwinds from markets, whether regulatory or otherwise, causing postponement in getting returns.
- Payback timeline: Management needs a minimum of 2 years for payback on cumulative capex from here on, and 2 to 3 years for the Warren Remedies capex specifically.
- No more major capex after this round: Only routine maintenance capex across sites. FY25 capex will be maintained at the committed ₹250 cr.
- API business doubling: The company invested close to ₹100 cr in an API facility at AURIC through Warren Remedies and expects to more than double the API business. The internal/external consumption ratio will flip from 60:40 to 40:60, selling roughly 60% of what is manufactured.
- D2C Oral Care facility: Set up at AURIC in Aurangabad with one line for manufacturing and packing, large enough to expand to 2 more lines including mouthwashes in future.
Aditi Panandikar: "Let me tell you very clearly that our strategy is correct. The decisions we made are also correct. Although some of the decisions have come in at a time when there have been massive headwinds that we had from the markets, whether regulatory or otherwise, and therefore, there has been postponement in getting returns from them."
Emerging Markets and Other Businesses
- Emerging markets growth expectation: 18% to 20% CAGR expected for the next couple of years.
- Remediation costs continuing: Expect at least another quarter at the same run rate of ₹4 cr per quarter.
- Peak debt: The company expects to borrow close to another ₹100 cr incremental beyond cash flow generated.
- FY26 materially different: Management stated FY26 "has to be" materially different.
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Plant corrections completion | Most plant-related corrections completed, enabling consistent supply | End of Q2 FY25 |
| U.S. revenue recovery | Consistent U.S. supply and strong revenues | From Q3 FY25 |
| EBITDA margin | Minimum 15% | Q3 FY25 |
| EBITDA margin | Minimum 15% for full year; Q4 stronger than Q3 | FY25 |
| Other expenses | Stabilize at ₹110 cr to ₹120 cr per quarter | Going forward |
| Capex | Maintain at ₹250 cr | FY25 |
| U.S. growth | 30% CAGR | Over next 2 years |
| Emerging markets growth | 18% to 20% CAGR | Next couple of years |
| API business | More than double | Going forward |
| API internal/external ratio | Flip from 60:40 to 40:60 (sell ~60%) | From this year |
| Cumulative capex payback | Minimum 2 years | From here on |
| Remediation costs | Continue at ~₹4 cr per quarter | At least one more quarter |
| Incremental debt | Borrow close to another ₹100 cr beyond cash flow | Unspecified |
Key Metrics
| Metric | Q1 FY25 |
|---|---|
| Net revenue | ₹394.2 cr, degrew 4.6% YoY vs ₹413.2 cr |
| EBITDA margin | 13.1% at ₹51.6 cr, vs 15.2% at ₹62.9 cr YoY |
| PAT margin | 3.8% at ₹15 cr, vs 6.3% at ₹25.9 cr YoY |
| EPS | ₹1.62, vs ₹2.81 same quarter last year |
| Domestic formulation revenue | ₹200.2 cr, vs ₹213 cr YoY |
| International formulation revenue | ₹157.1 cr, vs ₹159.7 cr YoY |
| US business revenue | ₹48.7 cr, vs ₹51.2 cr YoY; short of close to ₹20 cr in supply |
| Europe revenue | ₹75.4 cr, vs ₹79.4 cr YoY |
| Emerging markets revenue | ₹29.8 cr, vs ₹25.3 cr YoY |
| API business revenue | ₹31.2 cr, vs ₹35.7 cr YoY |
| AnaCipher CRO and Indoco Analytical Solutions revenue | ₹5.7 cr, grew ~20% YoY vs ₹4.8 cr |
| Remediation costs | ~₹4 cr per quarter, same run rate maintained |
| Short-term debt | ~₹350 cr |
| Long-term debt | ~₹250 cr (term loan ₹250 cr, other ₹284 cr) |
| D2C Oral Care revenue | ~₹25 cr from two variants |